Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030

Amid a flood of mostly bad news over its recent efforts in oncology, Gilead took a step back last week, presenting a long-term outlook at its prospects and showing how it plans to become a major cancer player by the end of the decade.